Sulzer's shareholders approved all proposals of Sulzer board of directors at the EGM held in Winterthur, Switzerland, on September 20, 2021. Due to the pandemic and in line with the COVID-19 Ordinance 3 of the Swiss Federal Council, shareholders did not attend the EGM in person. They were advised to authorize and instruct the independent proxy to cast their votes on their behalf. The independent proxy represented 79.13% of the share capital.
The Sulzer shareholders approved the demerger plan (a qualified majority of two thirds of the represented votes was required) and the incorporation of medmix, with a majority of more than 99.56%.
Grégoire Poux-Guillaume was elected as member and chairman of the board of directors of medmix, along with Jill Lee Ghim Ha and Marco Musetti who were elected as members of the board of directors, all of them for a one-year term. Grégoire Poux-Guillaume, Jill Lee Ghim Ha and Marco Musetti were also elected to serve on medmix' remuneration committee.
The Sulzer shareholders further approved the election of KPMG AG, Zurich, as auditors for medmix, and the election of Proxy Voting Services GmbH, Zurich, as the independent proxy for medmix. Finally, the shareholders approved the maximum aggregate compensation for the board of directions of medmix for the coming term of office, as well as the maximum aggregate compensation for the executive committee for the remainder of the financial year 2021 and for the financial year 2022.
The applications to the commercial register authorities in Zurich and Zug to register and, hence, formally effectuate the demerger and the incorporation of medmix will be filed today.
After the EGM, the newly elected board of directors of medmix held the first board meeting dealing, among other things, with the self-constitution of the medmix board. The medmix board members appointed Marco Musetti as vice-chairman. Jill Lee Ghim Ha will chair medmix' audit committee and Marco Musetti will chair the remuneration committee. The board of directors of medmix reiterated its intention to propose at least two additional independent members for election at the AGM in spring 2022.
We wish Girts Cimermans, leaving the executive committee of Sulzer AG due to the demerger and his team a lot of success at medmix.
As already announced in our press release dated September 6, 2021, the expected timetable for the listing of the medmix shares and the capital increase of medmix is the following: